Naltrexone is an opioid antagonist tablet used for adults with opioid use disorder or alcohol dependence. It helps after detoxification by blocking opioid receptors and reducing the rewarding effects of opioids, which can lower relapse risk.
Naltrexone is a type of opioid antagonist that blocks opioid receptors in the brain. When those receptors are blocked, opioids cannot produce their expected “high” or analgesic effect, so the brain gets less reinforcement from use.
Each tablet contains naltrexone hydrochloride as the active substance. The formulation may also include standard excipients such as fillers, binders, and disintegrants to form an oral pill suitable for swallowing.
Naltrexone is used as part of a supervised treatment plan for opioid dependence after detoxification and for relapse prevention in alcohol use disorder. It is prescribed for adults and must be started only when opioids are fully cleared from the body.
Naltrexone is used for:
It is not a detox medicine. It does not treat opioid withdrawal on its own, and it does not relieve cravings instantly for everyone. What it does well is reduce the “reward loop,” which is a big driver of relapse. WHO guidance on substance use treatment places medication as one part of care, with psychosocial support improving outcomes. [2]
Two key strengths show up in real practice: it is non‑sedating for most people, and it is not a controlled substance in many settings. A common limitation is adherence—missing doses removes the protective blockade.
Medication choice depends on the substance, relapse pattern, and patient stability. Naltrexone is often compared with medicines that serve a different job in care.
| Treatment | Primary role | Mechanism |
|---|---|---|
| Naltrexone | Relapse prevention in opioid or alcohol dependence | Opioid receptor antagonist (blocks reward from opioids; reduces alcohol reward pathways) |
| Naloxone | Emergency overdose reversal | Rapid opioid receptor antagonist that displaces opioids during overdose |
| Disulfiram | Alcohol aversion support | Alters alcohol metabolism, causing unpleasant reactions if alcohol is consumed |
A key practical difference: Naloxone is for emergencies, not daily relapse prevention. Disulfiram can work for selected alcohol-dependent patients who want a strong behavioural deterrent, yet it requires strict alcohol avoidance and careful monitoring. Naltrexone suits people aiming to reduce craving and reinforcement rather than creating an aversive reaction.
Some situations are clear “no” for Naltrexone, and others need close monitoring.
A blunt reality from clinic work: the most dangerous period is the transition. After detox, tolerance is lower; if someone stops Naltrexone and returns to prior opioid doses, overdose risk rises.
Because this medicine blocks opioid painkillers, your healthcare team should know about it before any dental treatment, surgery, or emergency care.
Most side effects are dose-related and show up early.
A small snack, good hydration, and consistent timing can reduce nausea for many people. Some patients do better taking it in the morning if it disrupts sleep; others prefer evening if it causes mild daytime fatigue.
Liver-related problems are uncommon but important: dark urine, yellowing of skin/eyes, persistent right‑upper abdominal pain, or severe fatigue should be treated as urgent symptoms. Any severe allergic reaction signs (swelling, wheeze, widespread rash) also need immediate care.
People make predictable mistakes with this medicine. Avoiding them saves a lot of trouble.
One more niche but real-life issue: urine drug screens can become part of employment or legal processes, and treatment plans sometimes need documentation. Organising those documents early is calmer than doing it during a crisis.
Doctors who prescribe Naltrexone often frame it as a relapse-prevention tool, not a cure. The goal is to reduce the “reward” from opioids or alcohol so behavioural strategies can actually stick week to week.
Clinicians also watch for two patterns: early nausea that resolves within days, and fatigue or sleep disturbance that can improve when dosing is moved to morning. Another observation is that patients with strong external structure (scheduled therapy, family support, supervised dosing at the start) tend to stay on the medication longer, which is where benefit accumulates. For opioid use disorder, many prescribers discuss where Naltrexone fits compared with opioid agonist therapy; for some patients, it is a great fit, and for others it is a mismatch because adherence is hard during high-stress periods. Guidance used across health systems, including resources aligned with WHO and regional frameworks, emphasises matching medication choice to patient stability and relapse risk rather than using one approach for everyone.
Naltrexone HCL is shorthand for naltrexone hydrochloride, the salt form used to make a stable oral medicine. Names like Naltrexone HCL Tablets, Naltrexone Hydrochloride Tablets, and Naltrexone Hydrochloride IP refer to the same active ingredient family, with differences driven by manufacturing standards and local pharmacopeia terms. The clinical effect comes from naltrexone itself once absorbed. Regulator and pharmacopeial naming conventions are widely standardised across health systems. Reference: MOHAP, 2023.
Safety and efficacy are not established for routine child dose use in the core indications of opioid or alcohol dependence, since most evidence and approvals focus on adults. Paediatric use, when considered, tends to be specialist-led for specific situations rather than standard addiction pathways. If a minor needs treatment for substance use, care is usually integrated with child and adolescent mental health services and family support. Reference: WHO, 2023.
Opioids (narcotics/opiate painkillers) can be blocked, so the person may feel little or no effect. Some people then take higher doses to try to overcome the blockade, which is dangerous if Naltrexone is missed or stopped, because tolerance is often lower after detox. A second risk is precipitated withdrawal if hidden opioid dependence is present at initiation. These risks are central in addiction-medicine guidance and regulator-reviewed prescribing information. Reference: FDA, 2023. [4]
Regular LFT monitoring is common, since liver enzyme elevations can occur and may not cause symptoms early on. Clinicians often check baseline LFTs and recheck after starting, then periodically during maintenance, with closer follow-up in people with hepatic risk factors. Symptoms like jaundice, dark urine, or persistent upper abdominal pain should be assessed urgently, even between scheduled tests. This approach is consistent with regulator-reviewed safety sections. Reference: FDA, 2023.
Long-acting injectable naltrexone can cause injection-site reactions, and severe reactions are uncommon but taken seriously in clinical settings. People with bleeding tendencies or on anticoagulants may need individual planning when injections are used, since intramuscular administration can bruise or bleed more easily. This product page is for tablets, yet patients sometimes switch forms within a treatment program, so it helps to understand both. Reference: Cochrane, 2020. [5]
سيتم تغليف طلبك بشكل آمن وشحنه خلال 24 ساعة. هذا هو الشكل الذي ستبدو عليه طردك بالضبط (صور لمنتج فعلي تم إرساله). له حجم ومظهر رسالة خاصة عادية (9.4×4.3×0.3 بوصة أو 24×11×0.7 سم) ولا يمكن رؤية محتوياته.
